Media

Recent News

• 15
  Sep
  2020

  Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

  Ottawa, ON /Business Wire/ September 15, 2020/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange to extend …Read More

• 09
  Sep
  2020

  Avivagen Inc. Announces Proposed Extension of Warrants

  Ottawa, ON /Business Wire/ September 9, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that it will be requesting approval from the TSX …Read More

• 03
  Sep
  2020

  Avivagen Inc. Announces Record Revenue for the Third Quarter Ending July 31, 2020

  • Significant increase in revenue driven by significant new and existing customer orders • Achieved product sales volume in Q3 equal to 85% of entire 2019 fiscal year volume • Customers’ purchasing patterns confirm a recurring revenue business model Ottawa, ON /Business Wire/ September 3rd, 2020 / Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”), …Read More

• 31
  Aug
  2020

  Avivagen To Present at The LD 500 Virtual Conference

  Ottawa, ON / August 31, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), , a life sciences company with a natural, approved and patented alternative to antibiotics, announced that it will be presenting at the LD 500 investor conference on Thursday, September 3rd at 9:40 AM EST. Kym Anthony, Chief Executive Officer will be presenting …Read More

• 18
  Aug
  2020

  Avivagen Announces Publication of Scientific Paper in British Journal of Nutrition

  Ottawa, ON / Business Wire / August 18, 2020 / – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce that a seminal paper, written …Read More

Media Coverage